Skip to main content
. 2017 Jun 27;8(45):79073–79086. doi: 10.18632/oncotarget.18674

Figure 1.

Figure 1

Proportion of patients treated with different doses of ruxolitinib over time, after stratification according to ruxolitinib starting doses (A: 5 mg BID; B: 10 mg BID; C: 15 mg BID; D: 20 mg BID). Percentages are calculated on evaluable patients at each time point. Ruxolitinib starting doses were mainly administered according to prescribing information (i.e.: 5 mg BID if platelet between 50 and 99 ×109/l, 15 mg BID if platelet between 100 and 199 ×109/l, 20 mg BID if platelet ≥ 200 ×109/l).